Advertisement
MILWAUKEE, Jan. 5, 2021 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated solely to cancer immunotherapy, has published a clinical practice guideline for use of immunotherapy in patients with lymphoma, a type of blood cancer with many different subtypes.
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma," was published in the Journal for ImmunoTherapy of Cancer (JITC), SITC's open access, peer-reviewed online journal. This immunotherapy-specific guideline for lymphoma was developed by an expert panel of leaders in the fields of hematology, oncology, oncology nursing and cancer patient advocacy from across the United States.
"Immunotherapies have risen to prominence as a cornerstone of lymphoma treatment, with some agents such as brentuximab vedotin and rituximab being widely adopted as standard components of first-line therapy, while the advent of approved CAR T cell therapies is now offering some patients with relapsed disease curative options for a cancer that was once almost universally fatal" said Michael R. Bishop, MD, co-chair of the SITC Lymphoma Immunotherapy Guideline Expert Panel. "The rapid and widespread adoption of immunotherapies is a massive paradigm shift for the oncology community, and these guidelines will provide clinicians the necessary expert guidance to use these exciting new treatments to care for their patients."
The SITC Cancer Immunotherapy Guidelines are developed by leading experts to help hematologists and oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines cover immunotherapy-specific treatment recommendations, toxicity management and considerations for optimizing patient quality of life. SITC has published clinical practice guidelines for acute leukemia, bladder carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma, immune effector cell-related adverse events, multiple myeloma, non-small cell lung cancer, prostate cancer and renal cell carcinoma. Additional guidelines are in development covering breast cancer, hepatocellular carcinoma, non-melanoma skin cancer and immune checkpoint inhibitor-related adverse events.
"This clinical practice guideline for the use of immunotherapy to treat lymphoma patients is part of our continued effort to disseminate best clinical practice recommendations based on evidence and consensus from our society's vast network of experts across the globe," said SITC Immediate Past President Mario Sznol, MD. "I believe the publications containing our society's Cancer Immunotherapy Guidelines program are an important resource for clinicians as the number and complexity of treatments increase across the entire spectrum of malignancies."
SITC is also offering additional opportunities to help clinicians access the guideline and implement the recommendations into their own practices. These resources include live webinars and on-demand modules hosted on the SITC website. On Jan. 25, 2021, SITC will host a live, free webinar during which attendees will be able to learn more about the treatment recommendations within the lymphoma guidelines and ask questions of expert faculty. Click here to view past SITC Cancer Immunotherapy Guidelines webinars on-demand.
About SITC Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
About JITC Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer featuring an impact factor of 10.252. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.
Media Contact
Laura Burns, SITC, 414-271-2456, [email protected]
Twitter, Facebook
SOURCE SITC
Advertisement
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma," was published in the Journal for ImmunoTherapy of Cancer (JITC), SITC's open access, peer-reviewed online journal. This immunotherapy-specific guideline for lymphoma was developed by an expert panel of leaders in the fields of hematology, oncology, oncology nursing and cancer patient advocacy from across the United States.
"Immunotherapies have risen to prominence as a cornerstone of lymphoma treatment, with some agents such as brentuximab vedotin and rituximab being widely adopted as standard components of first-line therapy, while the advent of approved CAR T cell therapies is now offering some patients with relapsed disease curative options for a cancer that was once almost universally fatal" said Michael R. Bishop, MD, co-chair of the SITC Lymphoma Immunotherapy Guideline Expert Panel. "The rapid and widespread adoption of immunotherapies is a massive paradigm shift for the oncology community, and these guidelines will provide clinicians the necessary expert guidance to use these exciting new treatments to care for their patients."
The SITC Cancer Immunotherapy Guidelines are developed by leading experts to help hematologists and oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines cover immunotherapy-specific treatment recommendations, toxicity management and considerations for optimizing patient quality of life. SITC has published clinical practice guidelines for acute leukemia, bladder carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma, immune effector cell-related adverse events, multiple myeloma, non-small cell lung cancer, prostate cancer and renal cell carcinoma. Additional guidelines are in development covering breast cancer, hepatocellular carcinoma, non-melanoma skin cancer and immune checkpoint inhibitor-related adverse events.
"This clinical practice guideline for the use of immunotherapy to treat lymphoma patients is part of our continued effort to disseminate best clinical practice recommendations based on evidence and consensus from our society's vast network of experts across the globe," said SITC Immediate Past President Mario Sznol, MD. "I believe the publications containing our society's Cancer Immunotherapy Guidelines program are an important resource for clinicians as the number and complexity of treatments increase across the entire spectrum of malignancies."
SITC is also offering additional opportunities to help clinicians access the guideline and implement the recommendations into their own practices. These resources include live webinars and on-demand modules hosted on the SITC website. On Jan. 25, 2021, SITC will host a live, free webinar during which attendees will be able to learn more about the treatment recommendations within the lymphoma guidelines and ask questions of expert faculty. Click here to view past SITC Cancer Immunotherapy Guidelines webinars on-demand.
About SITC Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
About JITC Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer featuring an impact factor of 10.252. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.bmj.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.
Media Contact
Laura Burns, SITC, 414-271-2456, [email protected]
Twitter, Facebook
SOURCE SITC
